Phase
Condition
Cytomegalovirus Infections
Treatment
LIVTENCITY
Clinical Study ID
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participants with post-transplant CMV infection and/or disease who are refractoryand/or resistant to one or more prior therapy including ganciclovir, valganciclovir,cidofovir or foscarnet.
Participants with age greater than or equal to (>=) 19 years.
Initiate first treatment course with maribavir.
Voluntarily consent to participate in the study.
Exclusion
Exclusion Criteria:
Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as perproduct label.
Participants previously treated with maribavir in any study or as marketed drug.
Participants actively participating in other clinical trials of post-transplant CMVinfection treatment or with other experimental treatments.
Study Design
Connect with a study center
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, 06591
Korea, Republic ofActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.